Therefore, it is suggested that the ctKRAS G12D mutation in the buffy coat could be applied as a surrogate biomarker for KRAS mutation and is a better diagnostic marker for the diagnosis of liquid biopsy compared from ascites in CRC patients. The gene discussed is KRAS; the disease is colorectal carcinoma.